vs

Side-by-side financial comparison of QUINSTREET, INC (QNST) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

QUINSTREET, INC is the larger business by last-quarter revenue ($287.8M vs $207.3M, roughly 1.4× Ultragenyx Pharmaceutical Inc.). QUINSTREET, INC runs the higher net margin — 17.4% vs -62.0%, a 79.5% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 1.9%). QUINSTREET, INC produced more free cash flow last quarter ($20.7M vs $-100.8M). Over the past eight quarters, QUINSTREET, INC's revenue compounded faster (53.2% CAGR vs 38.0%).

QuinStreet, Inc. is a publicly traded online marketing company based in Foster City, California. The company helps generate web traffic for clients by acquiring popular domain names.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

QNST vs RARE — Head-to-Head

Bigger by revenue
QNST
QNST
1.4× larger
QNST
$287.8M
$207.3M
RARE
Growing faster (revenue YoY)
RARE
RARE
+24.0% gap
RARE
25.9%
1.9%
QNST
Higher net margin
QNST
QNST
79.5% more per $
QNST
17.4%
-62.0%
RARE
More free cash flow
QNST
QNST
$121.5M more FCF
QNST
$20.7M
$-100.8M
RARE
Faster 2-yr revenue CAGR
QNST
QNST
Annualised
QNST
53.2%
38.0%
RARE

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
QNST
QNST
RARE
RARE
Revenue
$287.8M
$207.3M
Net Profit
$50.2M
$-128.6M
Gross Margin
9.6%
Operating Margin
0.4%
-54.7%
Net Margin
17.4%
-62.0%
Revenue YoY
1.9%
25.9%
Net Profit YoY
3342.5%
3.5%
EPS (diluted)
$0.87
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
QNST
QNST
RARE
RARE
Q4 25
$287.8M
$207.3M
Q3 25
$285.9M
$159.9M
Q2 25
$166.5M
Q1 25
$269.8M
$139.3M
Q4 24
$282.6M
$164.6M
Q3 24
$279.2M
$139.5M
Q2 24
$198.3M
$147.0M
Q1 24
$168.6M
$108.8M
Net Profit
QNST
QNST
RARE
RARE
Q4 25
$50.2M
$-128.6M
Q3 25
$4.5M
$-180.4M
Q2 25
$-115.0M
Q1 25
$4.4M
$-151.1M
Q4 24
$-1.5M
$-133.2M
Q3 24
$-1.4M
$-133.5M
Q2 24
$-2.2M
$-131.6M
Q1 24
$-7.0M
$-170.7M
Gross Margin
QNST
QNST
RARE
RARE
Q4 25
9.6%
Q3 25
9.4%
Q2 25
Q1 25
10.3%
Q4 24
9.5%
Q3 24
10.2%
Q2 24
8.8%
Q1 24
8.5%
Operating Margin
QNST
QNST
RARE
RARE
Q4 25
0.4%
-54.7%
Q3 25
1.7%
-106.9%
Q2 25
-64.8%
Q1 25
1.8%
-102.6%
Q4 24
-0.5%
-74.3%
Q3 24
-0.4%
-94.6%
Q2 24
-0.7%
-79.1%
Q1 24
-3.2%
-151.9%
Net Margin
QNST
QNST
RARE
RARE
Q4 25
17.4%
-62.0%
Q3 25
1.6%
-112.8%
Q2 25
-69.0%
Q1 25
1.6%
-108.5%
Q4 24
-0.5%
-80.9%
Q3 24
-0.5%
-95.7%
Q2 24
-1.1%
-89.5%
Q1 24
-4.2%
-156.8%
EPS (diluted)
QNST
QNST
RARE
RARE
Q4 25
$0.87
$-1.28
Q3 25
$0.08
$-1.81
Q2 25
$-1.17
Q1 25
$0.08
$-1.57
Q4 24
$-0.03
$-1.34
Q3 24
$-0.02
$-1.40
Q2 24
$-0.04
$-1.52
Q1 24
$-0.13
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
QNST
QNST
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$107.0M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$294.4M
$-80.0M
Total Assets
$493.0M
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
QNST
QNST
RARE
RARE
Q4 25
$107.0M
$421.0M
Q3 25
$101.3M
$202.5M
Q2 25
$176.3M
Q1 25
$81.8M
$127.1M
Q4 24
$57.8M
$174.0M
Q3 24
$25.0M
$150.6M
Q2 24
$50.5M
$480.7M
Q1 24
$39.6M
$112.3M
Stockholders' Equity
QNST
QNST
RARE
RARE
Q4 25
$294.4M
$-80.0M
Q3 25
$246.7M
$9.2M
Q2 25
$151.3M
Q1 25
$235.5M
$144.2M
Q4 24
$224.3M
$255.0M
Q3 24
$219.8M
$346.8M
Q2 24
$216.8M
$432.4M
Q1 24
$215.0M
$140.3M
Total Assets
QNST
QNST
RARE
RARE
Q4 25
$493.0M
$1.5B
Q3 25
$442.6M
$1.2B
Q2 25
$1.3B
Q1 25
$417.2M
$1.3B
Q4 24
$409.6M
$1.5B
Q3 24
$401.2M
$1.5B
Q2 24
$368.5M
$1.6B
Q1 24
$349.3M
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
QNST
QNST
RARE
RARE
Operating Cash FlowLast quarter
$21.6M
$-99.8M
Free Cash FlowOCF − Capex
$20.7M
$-100.8M
FCF MarginFCF / Revenue
7.2%
-48.6%
Capex IntensityCapex / Revenue
0.3%
0.5%
Cash ConversionOCF / Net Profit
0.43×
TTM Free Cash FlowTrailing 4 quarters
$106.9M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
QNST
QNST
RARE
RARE
Q4 25
$21.6M
$-99.8M
Q3 25
$19.6M
$-91.4M
Q2 25
$-108.3M
Q1 25
$30.1M
$-166.5M
Q4 24
$38.7M
$-79.3M
Q3 24
$-13.7M
$-67.0M
Q2 24
$16.6M
$-77.0M
Q1 24
$4.1M
$-190.7M
Free Cash Flow
QNST
QNST
RARE
RARE
Q4 25
$20.7M
$-100.8M
Q3 25
$18.4M
$-92.7M
Q2 25
$-110.7M
Q1 25
$29.5M
$-167.8M
Q4 24
$38.2M
$-79.5M
Q3 24
$-14.1M
$-68.6M
Q2 24
$15.4M
$-79.0M
Q1 24
$2.9M
$-193.9M
FCF Margin
QNST
QNST
RARE
RARE
Q4 25
7.2%
-48.6%
Q3 25
6.4%
-58.0%
Q2 25
-66.5%
Q1 25
10.9%
-120.5%
Q4 24
13.5%
-48.3%
Q3 24
-5.1%
-49.2%
Q2 24
7.8%
-53.7%
Q1 24
1.7%
-178.2%
Capex Intensity
QNST
QNST
RARE
RARE
Q4 25
0.3%
0.5%
Q3 25
0.4%
0.8%
Q2 25
1.5%
Q1 25
0.2%
1.0%
Q4 24
0.2%
0.1%
Q3 24
0.2%
1.2%
Q2 24
0.6%
1.4%
Q1 24
0.7%
3.0%
Cash Conversion
QNST
QNST
RARE
RARE
Q4 25
0.43×
Q3 25
4.32×
Q2 25
Q1 25
6.82×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

QNST
QNST

Financial Service$216.8M75%
Home Services And Other Revenue$71.0M25%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons